132131-24-9Relevant articles and documents
Synthesis of 7-[123I]idotacrine: A potential SPECT agent to map acetylcholinesterase
Akula, Murthy R.,Kabalka, George W.
, p. 959 - 964 (1999)
9-Amino-1,2,3,4-tetrahydroacridine (Tacrine), a cognitive enhancer, is an inhibitor of the enzyme acetylcholinesterase. The synthesis of no-carrier-added 7-[123I]iodotacrine, was accomplished in four steps for potential use in mapping acetylcholinesterase.
2-Cyano-4-iodo-acetanilide: A hydrogen-bonded chain of R 2 2(12) and R22(14) rings
Garden, Simon J.,Custodio, Cintia De A.,Wardell, James L.,Low, John N.,Glidewell, Christopher
, p. o408-o410 (2007)
The mol-ecules of 2-cyano-4-iodo-acetanilide, C9H7IN2O, are linked by N - H...N and C - H...O hydrogen bonds into chains of alternating R 2 2(12) and R 2 2(14) rings. International Union of Crystallography 2007.
Novel 4-arylaminoquinazolines bearing N,N-diethyl(aminoethyl)amino moiety with antitumour activity as EGFRwt-TK inhibitor
Zhang, Yaling,Chen, Li,Li, Xiabing,Gao, Li,Hao, Yunxia,Li, Baolin,Yan, Yaping
, p. 1668 - 1677 (2019/10/14)
Herein, four novel 4-arylaminoquinazoline derivatives with N,N-diethyl(aminoethyl)amino moiety were designed, synthesised and evaluated on biological activities in vitro. All synthesised compounds have inhibitory effects against tumour cells (SW480, A549, A431 and NCI-H1975). In particular, 4-(3-chloro-4-(3-fluorobenzyloxy)phenylamino)-6-(5-((N,N-diethyl(aminoethyl))aminomethyl)furan-2-yl)quinazoline (6a) and 6-(5-((N,N-diethylethyl)aminomethyl)furan-2-yl)-4-(4-(E)-(propen-1-yl)phenylamino)quinazoline (6d) were potent antitumour agents which showed high antiproliferative activities against tumour cells in vitro. Moreover, compound 6a could induce late apoptosis of A549 cells at high concentrations and arrest cell cycle of A549 cells in the G0/G1 phase at tested concentrations. Also, compound 6a could inhibit the activity of wild type epidermal growth factor receptor tyrosine kinase (EGFRwt-TK) with IC50 value of 15.60 nM. Molecular docking showed that compound 6a formed three hydrogen bonds with EGFRwt-TK, while lapatinib formed only two hydrogen bonds with the receptor protein. It is believed that this work would be giving a reference for developing anti-cancer drugs targeted EGFR-TK.
Lapatinib intermediate and its preparation method and application
-
Paragraph 0041-0043, (2016/10/09)
The invention discloses a lapatinib intermediate as well as a preparation method and application thereof. The lapatinib intermediate contains chemical structures respectively shown in a formula IV, a formula V and a formula VIII (described in the specification). The lapatinib intermediate provided by the invention has the advantages of simple preparation technology, available raw materials, mild reaction conditions, high yield, easy control on quality and the like; by applying the lapatinib intermediate, a preparation route of lapatinib can be shortened, operation is simple, reaction conditions are mild, especially adoption of poisonous reagents such as sulfoxide chloride and phosphorus oxychloride can be avoided, the lapatinib intermediate can be stable in each step, post treatment is simple, yield is high, the lapatinib intermediate is applicable to mass production and has practical value, and large-scale industrial production demand of lapatinib can be met.